Familial hypercholesterolaemia in Finland: common, rare and mild mutations of the LDL receptor and their clinical consequences

References

• Goldstein J L, Hobbs H H, Brown M S. Familial hypercholesterolemia. The metabolic bases of inherited diseases. 7th edn., C R Scriver, A L Beaudet, W S Sly, D Valle. McGraw-Hill Book Co., New York, NY 1995; 1981–2030
   Google Scholar
• Brown M S, Goldstein J L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34–47
   PubMed Web of Science ®Google Scholar
• Brown M S, Kovanen P T, Goldstein J L. Regulation of plasma cholesterol by lipoprotein receptors. Science 1981; 212: 628–35
   PubMed Web of Science ®Google Scholar
• Thompson G R, Seed M, Niththyananthan S, McCarthy S, Thorogood M. Genotypic and phenotypic variation in familial hypercholesterolemia. Arteriosclerosis 1989; 9((Suppl 1))1–75, 80
   PubMedGoogle Scholar
• Nevanlinna H R. The Finnish population structure. A genetic and genealogical structure. Hereditas 1972; 71: 195–236
   PubMed Web of Science ®Google Scholar
• Peltonen L, Jalanko A, Varilo T. Molecular genetics of the Finnish disease heritage. Hum Mol Gen 1999; 8: 1913–23
   PubMed Web of Science ®Google Scholar
• Levy E, Haltia M, Fernandez-Madrid I, Koivunen O, Ghiso J, Prelli F, Frangione B. Mutation in gelsolin gene in Finnish hereditary amyloidosis. J Exp Med 1990; 172: 1865–7
   PubMed Web of Science ®Google Scholar
• Aaltonen L A, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomäki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 339: 924–5
   Google Scholar
• Piippo K, Laitinen P, Swan H, Toivonen L, Viitasalo M, Pasternack M, et al. Homozygosity for a HERG potassium channel mutation causes a severe form of long QT syndrome: identification of an apparent founder mutation in the Finns. J Am Coll Cardiol 2000; 35: 1919–25
   PubMed Web of Science ®Google Scholar
• Piippo K, Swan H, Pasternack M, Chapman H, Paavonen K, Viitasalo M, et al. A founder mutation of the potassium channel KCNQ1 in long QT syndrome: implications for estimation of disease prevalence and molecular diagnostics. J Am Coll Cardiol 2001; 37: 562–8
   PubMed Web of Science ®Google Scholar
• Aalto-Setälä K, Helve E, Kovanen P T, Kontula K. Finnish type of low density lipoprotein receptor mutation (FH-Helsinki) deletes exons encoding the carboxy-terminal part of the receptor and creates an internalization-defective phenotype. J Clin Invest 1989; 84: 499–505
   PubMed Web of Science ®Google Scholar
• Aalto-Setälä K, Koivisto U -M, Miettinen T A, Gylling H, Kesaniemi Y A, Savolainen M, et al. Prevalence and geographical distribution of major LDL receptor gene rearrangements in Finland. J Int Med 1992; 231: 227–34
   PubMed Web of Science ®Google Scholar
• Koivisto U -M, Turtola H, Aalto-Setälä K, Top B, Frants R R, Kontula K. The familial hypercholesterolemia (FH)-North Karelia mutation of the low density lipoprotein receptor gene deletes seven nucleotides of exon 6 and is a common cause of FH in Finland. J Clin Invest 1992; 90: 219–28
   PubMed Web of Science ®Google Scholar
• Koivisto U -M, Palvimo J J, Jänne O A, Kontula K. A single-base substitution in the proximal Sp1 site of the human low density lipoprotein receptor promoter as a cause of heterozygous familial hypercholesterolemia. Proc Natl Acad Sci USA 1994; 91: 10526–30
   PubMed Web of Science ®Google Scholar
• Koivisto U -M, Viikari J S, Kontula K. Molecular characterization of minor gene rearrangements in Finnish patients with heterozygous familial hypercholesterolemia: identification of two common missense mutations (Gly823->Asp and Leu380->His) and eight rare mutations of the LDL receptor gene. Am J Hum Genet 1995; 57: 789–97
   PubMed Web of Science ®Google Scholar
• Koivisto U -M, Kontula K. A novel deletion/inversion mutation in the low density lipoprotein receptor as a cause of heterozygous familial hypercholesterolemia. Hum Mutat 1996; 8: 326–32
   PubMed Web of Science ®Google Scholar
• Koivisto U -M, Gylling H, Miettinen T A, Kontula K. Familial moderate hypercholesterolemia caused by Asp235->Glu mutation of the LDL receptor gene and co-occurence of a de novo deletion of the LDL receptor gene in the same family. Arterioscler Thromb Vasc Biol 1997; 17: 1392–9
   PubMed Web of Science ®Google Scholar
• Koivisto P V, Koivisto U -M, Kovanen F T, Gylling H, Miettinen T A, Kontula K. Deletion of exon 15 of the LDL receptor gene is associated with a mild form of familial hypercholesterolemia. Arterioscler Thromb 1993; 13: 1680–8
   PubMed Web of Science ®Google Scholar
• Vuorio A F, Turtola H, Kontula K. A novel point mutation (Pro to Ser) of the low density lipoprotein receptor gene in a family with moderate hypercholesterolemia. Clin Genet 1997; 51: 191–5
   PubMed Web of Science ®Google Scholar
• Nissen H, Guldberg P, Bo Hansen A, Petersen N E, Herder M. Clinically applicable mutation screening in familial hypercholesterolemia. Hum Mutat 1996; 8: 168–77
   PubMed Web of Science ®Google Scholar
• Varret M, Rabés J -P, Thiart R, Kotze M J, Baron H, Cenarro A, et al. LDLR database (second edition): new additions to the database and the sofware, and results on the first molecular analysis. Nucleic Acids Res 1998; 26: 248–52
   PubMed Web of Science ®Google Scholar
• Vuorio A F, Turtola H, Piilahti K -M, Repo P, Kanninen T, Kontula K. Familial hypercholesterolemia in the Finnish North Karelia: a molecular, clinical and genealogical study. Arterioscler Thromb Vasc Biol 1997; 17: 3127–38
   PubMed Web of Science ®Google Scholar
• Moojani S, Roy M, Torres A, Betard C, Gagné C, Lambert M, et al. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolemia. Lancet 1993; 341: 1303–6
   PubMed Web of Science ®Google Scholar
• Kotze M J, Villiers W JS, Steyen K, Kriek J A, Marais A D, Langenhoven E, et al. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb 1993; 13: 1460–8
   PubMed Web of Science ®Google Scholar
• Gudnason V, Patel D, Sun X -M, Humphries S, Soutar A K, Knight B L. Effect of the StuI polymorphism in the LDL receptor gene (Ala370 to Thr) on lipid levels in healthy individuals. Clin Genet 1995; 47: 68–74
   PubMed Web of Science ®Google Scholar
• Graadt van Roggen J F, van der Westhuyzen D R, Coetzee G A, Marais A D, Steyen K, Langenhoven E, et al. FH Afrikaner-3 LDL receptor mutation results in defective LDL receptors and causes a mild form of familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 765–72
   PubMed Web of Science ®Google Scholar
• Sun X -M, Neuwirth C, Wade D P, Knight B L, Soutar A K. A mutation (T-45C) in the promoter region of the low-density-lipoprotein (LDL)-receptor gene is associated with a mild clinical phenotype in a patient with heterozygous familial hypercholesterolemia. Hum Mol Genet 1995; 4: 2125–9
   PubMed Web of Science ®Google Scholar
• Hobbs H H, Brown M S, Russell D W, Davignon J, Goldstein J L. Deletion in the gene for the low-density lipoprotein receptor in a majority of French Canadian with familial hypercholesterolemia. N Engl J Med 1987; 317: 734–7
   PubMed Web of Science ®Google Scholar
• Leitersdorf E, Van der Westhuyzen D R, Coetzee G A, Hobbs H H. Two common low density lipoprotein receptor gene mutations cause familial hypercholesterolemia in Afrikaners. J CIin Invest 1989; 84: 954–61
   PubMed Web of Science ®Google Scholar
• Kotze M J, Langenhoven E, Warnich L, Du Plessis L, Retief A E. The molecular basis and diagnosis of familial hypercholesterolemia in South African Afrikaners. Ann Hum Genet 1991; 55: 115–21
   PubMed Web of Science ®Google Scholar
• Vuorio A F, Turtola H, Kontula K. Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with a molecularly defined familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 3332–7
   PubMed Web of Science ®Google Scholar
• Sijbrands E JG, Westendorp R GJ, Defesche J C, deMeier P HEM, Smelt A HM, Kastelein J JP. Mortality over two centuries in large pedigree with familial hypercholesterolemia: family tree mortality study. BMJ 2001; 332: 1019–23
   Google Scholar
• Netea M G, Demacker P NM, Kullberg B J, Boerman O C, Verschueren I, Stalenhoef A FH, et al. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J Clin Invest 1996; 97: 1366–72
   PubMed Web of Science ®Google Scholar
• Koivisto U -M, Hämäläinen L, Tarkinen M -R, Kettunen K, Kontula K. Prevalence of familial hypercholesterolemia among young North Karelian patients with coronary heart disease: a study based on diagnosis by polymerase chain reaction. J Lipid Res 1993; 34: 269–77
   PubMed Web of Science ®Google Scholar
• Vuorio A F, Kontula K, Turtola K, Sajantila A. Post-mortem molecularly defined familial hypercholesterolemia and sudden cardiac death of young men. Forensic Sci Int 1999; 106: 87–92
   PubMed Web of Science ®Google Scholar
• Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989; 79: 225–32
   PubMed Web of Science ®Google Scholar
• Wiklund O, Angelin B, Olofsson S O, Eriksson M, Fager G, Berglund L, et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990; 335: 1360–3
   PubMed Web of Science ®Google Scholar
• Sharp S D, Williams R R, Hunt S C, Schumacher M C. Coronary risk factors and the severity of angiographic coronary artery disease in members of high-risk pedigrees. Am Heart J 1992; 123: 279–85
   PubMed Web of Science ®Google Scholar
• Tatò F, Keller C, Schuster H, Spengel H, Wolfram G, Zöllner N. Relation of lipoprotein(a) to coronary heart disease and duplex-sonographic findings in heterozygous familial hypercholesterolemia. Atherosclerosis 1993; 101: 69–77
   PubMed Web of Science ®Google Scholar
• Sudhir K, Ports T A, Amidon T H, Goldberger J J, Bhushan V, Kane J P, et al. Increased prevalence of coronary ectasia in heterozygous familial hypercholesterolemia. Circulation 1995; 91: 1375–80
   PubMed Web of Science ®Google Scholar
• Ferriéres J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 1995; 92: 290–5
   PubMed Web of Science ®Google Scholar
• Gagne C, Moojani S, Brun D, Toussaint M, Lupien P -J. Heterozygous familial hypercholesterolemia. Relationship between plasma lipids, lipoproteins, clinical manifestation and ischaemic heart disease in men and women. Atherosclerosis 1979; 34: 13–24
   PubMed Web of Science ®Google Scholar
• Hill J S, Hayden M R, Frohlich J, Prithard H. Genetic and enviromental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991; 11: 290–7
   PubMed Web of Science ®Google Scholar
• Mbew A D, Bhatnagar D, Durringrton P N, Hunt L, Ishola M, Arrol S, et al. Serum lipoprotein(a) in patients for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb 1991; 11: 940–6
   PubMed Web of Science ®Google Scholar
• Beaumont V, Jacotot B, Beaumont J -L. Ischaemic disease on men and women with familial hypercholesterolemia and xanthomatosis. Atherosclerosis 1976; 24: 441–50
   PubMed Web of Science ®Google Scholar
• Miettinen T A, Gylling H. Mortality and cholesterol metabolism in familial hypercholesterolemia. Arteriosclerosis 1988; 8: 163–7
   PubMedGoogle Scholar
• Utermann G, Pruin N, Steinmetz A. Polymorphism of apolipoprotein E. Effect of single polymorphic gene locus on plasma levels in man. Clin Genet 1979; 15: 63–72
   PubMed Web of Science ®Google Scholar
• Bouthillier D, Sing C F, Davignon J. Apolipoprotein E phenotyping with a single gel method: application to the study of informative matings. J Lipid Res 1983; 24: 1060–9
   PubMed Web of Science ®Google Scholar
• Kuusi T, Nieminen M S, Ehnholm C, Yki-Järvinen H, Valle M, Nikkilä E A, et al. Apoprotein E polymorphism and coronary artery disease. Increased prevalence of apolipoprotein E4 in angiographically verified coronary patients. Arteriosclerosis 1989; 9: 237–41
   PubMedGoogle Scholar
• Emi M, Hegele R M, Hopkins P N, Wu L L, Plaetke R, Williams R R, et al. Effects of three genetic loci in a pedigree with multiple lipoprotein phenotypes. Arterioscler Thromb 1991; 11: 1349–55
   PubMed Web of Science ®Google Scholar
• Huang Y, Liu X Q, Rall S C, Jr, Mahley R W. Hypolow density lipoprotein cholesterol effect in apolipoprotein E2 transgenic mice is caused by impaired lipoprotein lipase-mediated lipolysis or triglyceride-rich lipoproteins (abstract). Circulation 1997; 96((Suppl 8))1–39
   Web of Science ®Google Scholar
• Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J 1998; 19((Suppl A))A12–9
   PubMed Web of Science ®Google Scholar
• Kontula K, Vuorio A, Turtola H, Saikku P. Association of seropositivity for Chlamydia pneumoniae and coronary artery disease in heterozygous familial hypercholesterolaemia. Lancet 1999; 354: 46–7
   PubMed Web of Science ®Google Scholar
• Sparrow C P, Burton C A, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115–21
   PubMed Web of Science ®Google Scholar
• Strong J P, Malcom G T, McMahan C A, Tracy R E, Newman W P, Herderick E E, et al. Prevalence and extent of atherosclerosis in adolescents and young adults. Implications for prevention from the pathobiological determinants of atherosclerosis in youth study. JAMA 1999; 281: 727–35
   PubMed Web of Science ®Google Scholar
• Napoli C, D'Armiento F P, Mancini F P, Witztum J L, Palumbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enchanced by maternal hypercholesterolemia: intimal accumulation of LDL and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997; 100: 2680–90
   PubMed Web of Science ®Google Scholar
• Napoli C, Glass C K, Witztum J L, Deutsch R, D'Armiento F P, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: fate of early lesions in children (FELIC) study. Lancet 1999; 354: 1234–41
   PubMed Web of Science ®Google Scholar
• Brizzi P, Tonolo G, Esposito F, Puddu L, Dessole S, Maioli M, et al. Lipoprotein metabolism during normal pregnancy. Am J Obstet Gynecol 1999; 181: 430–4
   PubMed Web of Science ®Google Scholar
• Martin U, Davies C, Hayavi S, Hartland A, Dunne F. Is normal pregnancy atherogenic. Clin Sci 1999; 96: 421–5
   PubMed Web of Science ®Google Scholar
• Glueck C J, Christopher C, Tsang R C, Mellies M J. Cholesterol-free diet and the physiologic hyperlipidemia of pregnancy in familial hypercholesterolemia. Metabolism 1980; 29: 949–55
   PubMed Web of Science ®Google Scholar
• Celemajer D S, Sorensen K E, Gooch V M, Spiegelhalter D J, Miller O I, Sullivan I D, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111–5
   PubMed Web of Science ®Google Scholar
• Tonstad S, Joakimsen O, Stensland-Bugge E, Leren T P, Ose L, Russell D, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and controls. Arterioscler Thromb Vasc Biol 1996; 16: 984–91, 67
   PubMed Web of Science ®Google Scholar
• WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization WHO MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583–612
   PubMed Web of Science ®Google Scholar
• Miettinen T A, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995; 333: 1308–12
   PubMed Web of Science ®Google Scholar
• Vuorio A F, Gylling H, Turtola H, Kontula K, Ketonen P, Miettinen T A. Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation. Arterioscler Thromb Vasc Biol 2000; 20: 500–6
   PubMed Web of Science ®Google Scholar
• Gylling H, Siimes M A, Miettinen T A. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J Lipid Res 1995; 36: 1807–12
   PubMed Web of Science ®Google Scholar
• Lichtenstein A H, Deckelbaum R J. AHA Science Advisory. Stanol/sterol ester-containing foods and blood cholesterol levels. A statement for healthcare professionals from the Nutrition Committee of the Council of Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 2001; 103: 1177–9
   PubMed Web of Science ®Google Scholar
• Stein E A, Illingworth D R, Kwiterowich P O, Jr., Liacouras C A, Siimes M A, Jacobson M S, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. IAMA 1999; 281: 137–44
   PubMed Web of Science ®Google Scholar